95 related articles for article (PubMed ID: 15127968)
1. Tailoring immunosuppressive therapy in interstitial lung diseases.
Agostini C
Sarcoidosis Vasc Diffuse Lung Dis; 2004 Mar; 21(1):3-9. PubMed ID: 15127968
[TBL] [Abstract][Full Text] [Related]
2. Advances in immunosuppressive therapy.
Marder W; McCune WJ
Semin Respir Crit Care Med; 2007 Aug; 28(4):398-417. PubMed ID: 17764058
[TBL] [Abstract][Full Text] [Related]
3. New immunosuppressive drugs: an update.
Pohanka E
Curr Opin Urol; 2001 Mar; 11(2):143-51. PubMed ID: 11224744
[TBL] [Abstract][Full Text] [Related]
4. Therapies for interstitial lung disease: past, present and future.
Kim R; Meyer KC
Ther Adv Respir Dis; 2008 Oct; 2(5):319-38. PubMed ID: 19124380
[TBL] [Abstract][Full Text] [Related]
5. [Treatment in diffuse interstitial lung diseases].
Kayacan O
Tuberk Toraks; 2005; 53(2):190-9. PubMed ID: 16100659
[TBL] [Abstract][Full Text] [Related]
6. Tailoring immunosuppressive therapy.
Kuypers DR; Vanrenterghem YC
Nephrol Dial Transplant; 2002 Dec; 17(12):2051-4. PubMed ID: 12454210
[No Abstract] [Full Text] [Related]
7. Immunosuppressive therapy for autoimmune lung diseases.
Meyer KC; Bierach J
Immunol Allergy Clin North Am; 2012 Nov; 32(4):633-69. PubMed ID: 23102070
[TBL] [Abstract][Full Text] [Related]
8. Immunosuppressive agents and interstitial lung disease: what are the risks?
Meyer KC
Expert Rev Respir Med; 2014 Jun; 8(3):263-6. PubMed ID: 24649876
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic intervention: assessing the role of the international consensus guidelines.
Nathan SD
Chest; 2005 Nov; 128(5 Suppl 1):533S-539S. PubMed ID: 16304244
[TBL] [Abstract][Full Text] [Related]
10. Cyclophosphamide in scleroderma lung disease.
Kuschner WG
N Engl J Med; 2006 Sep; 355(11):1173; author reply 1174. PubMed ID: 16971726
[No Abstract] [Full Text] [Related]
11. Treatment of interstitial lung diseases associated with connective tissue diseases.
Kobayashi A; Okamoto H
Expert Rev Clin Pharmacol; 2012 Mar; 5(2):219-27. PubMed ID: 22390563
[TBL] [Abstract][Full Text] [Related]
12. The evolving pharmacotherapy of pulmonary fibrosis.
Lota HK; Wells AU
Expert Opin Pharmacother; 2013 Jan; 14(1):79-89. PubMed ID: 23265249
[TBL] [Abstract][Full Text] [Related]
13. [Immunosuppressive therapy in clinical practice].
Frey FJ
Schweiz Med Wochenschr; 1987 May; 117(21):810-5. PubMed ID: 3589636
[TBL] [Abstract][Full Text] [Related]
14. Immunosuppressive therapy in lung transplantation: state of the art.
Korom S; Boehler A; Weder W
Eur J Cardiothorac Surg; 2009 Jun; 35(6):1045-55. PubMed ID: 19349186
[TBL] [Abstract][Full Text] [Related]
15. Acute exacerbations of interstitial lung diseases.
Papanikolaou IC; Drakopanagiotakis F; Polychronopoulos VS
Curr Opin Pulm Med; 2010 Sep; 16(5):480-6. PubMed ID: 20473169
[TBL] [Abstract][Full Text] [Related]
16. The mode of action of immunosuppressive agents.
Bach JF
Front Biol; 1975; 41():1-374. PubMed ID: 1052787
[No Abstract] [Full Text] [Related]
17. [Efficacy of ab initio immunosuppressive therapy and steroid-sparing effect in interstitial lung disease associated with antisynthetase antibody syndrome].
Franzolini N; Quartuccio L; De Marchi G; De Vita S
Reumatismo; 2007; 59(3):202-8. PubMed ID: 17898879
[TBL] [Abstract][Full Text] [Related]
18. Interstitial pneumonitis as an adverse reaction to mTOR inhibitors.
Molas-Ferrer G; Soy-Muner D; Anglada-MartÃnez H; Riu-Viladoms G; Estefanell-Tejero A; Ribas-Sala J
Nefrologia; 2013; 33(3):297-300. PubMed ID: 23712219
[TBL] [Abstract][Full Text] [Related]
19. [Toxicity management for mTOR inhibitors].
Mukohara T
Nihon Rinsho; 2015 Feb; 73 Suppl 2():272-6. PubMed ID: 25831766
[No Abstract] [Full Text] [Related]
20. [Mechanism of action of immunosuppressive drugs].
Dimitriu CG; Zeana C
Med Interna (Bucur); 1972 Aug; 24(8):977-83. PubMed ID: 5080894
[No Abstract] [Full Text] [Related]
[Next] [New Search]
